Key Takeaways Exact Sciences posted Q2 EPS of $0.22 versus a loss of $0.09 last year, beating estimates.EXAS' Q2 revenues rose 16% to $811.1M, led by Cologuard and Oncotype growth.EXAS lifts 2025 revenue forecast to $3.13-$3.17B, with the EBITDA outlook also increased.Exact Sciences Corporation (EXAS) reported earnings per share (EPS) of 22 cents in the second quarter of 2025 compared to the Zacks Consensus Estimate of a loss of 2 cents. The reported figure compares favorably with a loss of 9 cents in the s ...